Covered recipient · General Payments record
BRIAN D MODENA
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$19,150.51
197 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,254.75 | 4 |
| Food and Beverage | $4,943.07 | 184 |
| Honoraria | $2,544.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,300.00 | 1 |
| Travel and Lodging | $1,085.93 | 5 |
| Education | $22.76 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $8,336.94 | 36 |
| Regeneron Pharmaceuticals, Inc. | $2,788.75 | 2 |
| Blueprint Medicines Corporation | $2,671.98 | 5 |
| SANOFI US SERVICES INC. | $1,266.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $863.21 | 30 |
| GENZYME CORPORATION | $725.43 | 26 |
| Amgen Inc. | $583.19 | 17 |
| Regeneron Healthcare Solutions, Inc. | $348.11 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. | $263.19 | 10 |
| LEO Pharma Inc. | $236.61 | 15 |
| PFIZER INC. | $217.84 | 11 |
| Novartis Pharmaceuticals Corporation | $122.22 | 5 |
| Grifols USA, LLC | $99.82 | 4 |
| Neurent Medical Limited | $78.76 | 1 |
| Pharming Healthcare, Inc. | $75.57 | 3 |
| Genentech USA, Inc. | $73.69 | 3 |
| ABBVIE INC. | $65.95 | 3 |
| Phadia US Inc. | $60.09 | 3 |
| Optinose US, Inc. | $47.58 | 2 |
| Octapharma USA, Inc. | $45.37 | 2 |
| Genentech, Inc. | $36.76 | 1 |
| BioCryst US Sales Co., LLC | $32.40 | 1 |
| Lilly USA, LLC | $31.32 | 1 |
| CSL Behring | $30.76 | 1 |
| Incyte Corporation | $29.27 | 1 |
| kaleo, Inc. | $19.70 | 1 |
Page 4 of 4; records 151–197 of 197 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRIAN D MODENA
NPI 1235379207 · CMS profile ID 237625
Allopathic & Osteopathic Physicians / Allergy & Immunology
LA JOLLA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–197 of 197 matching records. This page contains 47 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1235379207?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–197 of 197 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235379207?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–197 of 197 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235379207?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–197 of 197 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235379207?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
197 matching records · $19,150.51 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–197 of 197.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| kaleo, Inc. | $19.70 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126623286 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.02 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105391254 | CMS |
| GENZYME CORPORATION | $43.75 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782993 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.99 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104292472 | CMS |
| AstraZeneca Pharmaceuticals LP | $9.00 | 03/05/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104368741 | CMS |
| Octapharma USA, Inc. | $23.09 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142317172 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.14 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137636966 | CMS |
| Amgen Inc. | $63.65 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111654279 | CMS |
| GENZYME CORPORATION | $30.31 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139783007 | CMS |
| Grifols USA, LLC | $23.51 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124737507 | CMS |
| Amgen Inc. | $36.41 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117631855 | CMS |
| AstraZeneca Pharmaceuticals LP | $135.00 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155841446 | CMS |
| Regeneron Pharmaceuticals, Inc. | $970.00 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114402795 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,818.75 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114402797 | CMS |
| Blueprint Medicines Corporation | $2,544.00 | 02/22/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147456423 | CMS |
| Blueprint Medicines Corporation | $50.00 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147456425 | CMS |
| Blueprint Medicines Corporation | $17.00 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147456427 | CMS |
| GENZYME CORPORATION | $9.67 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139783009 | CMS |
| GlaxoSmithKline, LLC. | $6.90 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116335815 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.97 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104346678 | CMS |
| GlaxoSmithKline, LLC. | $25.83 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116526878 | CMS |
| AstraZeneca Pharmaceuticals LP | $66.39 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104381761 | CMS |
| Regeneron Healthcare Solutions, Inc. | $48.45 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114117004 | CMS |
| Amgen Inc. | $43.66 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111654277 | CMS |
| Genentech, Inc. | $36.76 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132982781 | CMS |
| GlaxoSmithKline, LLC. | $22.94 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116176825 | CMS |
| GENZYME CORPORATION | $49.76 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782979 | CMS |
| GlaxoSmithKline, LLC. | $52.99 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116254840 | CMS |
| PFIZER INC. | $18.88 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131535669 | CMS |
| Amgen Inc. | $46.13 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111654275 | CMS |
| GlaxoSmithKline, LLC. | $25.88 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116321939 | CMS |
| GENZYME CORPORATION | $12.50 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782973 | CMS |
| LEO Pharma Inc. | $0.70 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152643161 | CMS |
| LEO Pharma Inc. | $29.16 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152643163 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.09 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104207165 | CMS |
| GENZYME CORPORATION | $6.54 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782983 | CMS |
| Amgen Inc. | $22.26 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111654273 | CMS |
| Novartis Pharmaceuticals Corporation | $22.79 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087079522 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 01/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116088646 | CMS |
| GENZYME CORPORATION | $46.24 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782977 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.89 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105242810 | CMS |
| GENZYME CORPORATION | $5.72 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782971 | CMS |
| GENZYME CORPORATION | $38.07 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782999 | CMS |
| GENZYME CORPORATION | $16.61 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139782975 | CMS |
| ABBVIE INC. | $25.68 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105048940 | CMS |
| AstraZeneca Pharmaceuticals LP | $51.06 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105358945 | CMS |
| PFIZER INC. | $24.44 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131559889 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,778.32 | 7 |
| PY2025 | Principal investigator | $737,587.24 | 89 |
| PY2024 | Principal investigator | $240,924.19 | 371 |
| PY2023 | Recipient | $1,250.00 | 3 |
| PY2023 | Principal investigator | $91,240.33 | 47 |
| PY2022 | Recipient | $3,000.00 | 8 |
| PY2022 | Principal investigator | $41,561.64 | 5 |
| PY2021 | Recipient | $3,940.75 | 3 |
| PY2021 | Principal investigator | $116,702.28 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
96 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,365.21 | 12/24/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192186976 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,083.60 | 12/24/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192188357 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,018.40 | 12/22/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121840 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,997.00 | 12/22/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121848 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,785.00 | 12/22/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121852 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,260.00 | 12/18/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244050732 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 12/12/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101671 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,588.85 | 12/12/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101677 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 12/12/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101695 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,265.15 | 12/12/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101702 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,160.04 | 12/11/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192186990 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,800.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 11/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266525 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $20,299.00 | 11/24/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE TH | No dispute reported | 06/30/2026 | 1192186981 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $926.10 | 11/17/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121818 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,655.00 | 11/10/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121802 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,225.00 | 11/10/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121809 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 11/07/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101708 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,150.00 | 11/04/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121814 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,572.00 | 11/04/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121821 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,646.00 | 10/27/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121793 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,161.00 | 10/27/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121797 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,020.00 | 10/20/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121779 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,320.80 | 10/20/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,085.21 | 10/17/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251293 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $28,250.00 | 10/15/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101595 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,000.00 | 10/15/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226101615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,460.00 | 10/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121760 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $400.00 | 10/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121763 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $38,196.05 | 10/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226121769 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,900.00 | 10/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226121772 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $926.10 | 10/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121776 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,674.00 | 10/06/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121755 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,821.17 | 09/18/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192188349 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,445.00 | 09/08/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121744 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,881.70 | 09/03/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121742 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $28,184.00 | 08/25/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121512 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,800.00 | 08/25/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121739 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 08/18/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121508 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $926.10 | 08/11/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121498 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,690.00 | 08/11/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121504 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 07/28/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121491 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $31,851.60 | 07/22/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192188345 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,214.00 | 07/21/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) | No dispute reported | 06/30/2026 | 1226121469 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,420.80 | 07/21/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121482 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 07/21/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121487 |
| Principal investigator 1 | Blueprint Medicines Corporation | $27,677.50 | 07/16/2025 | Non-covered Recipient Entity Modena Allergy & Asthma Clinical Research - La Jolla | BLU-808-1201 | No dispute reported | 06/30/2026 | 1235785607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37,830.00 | 07/14/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121479 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,341.70 | 07/07/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121463 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,766.19 | 07/02/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121474 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,164.14 | 05/22/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192188353 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,656.48 | 05/05/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121454 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25,217.62 | 04/24/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192186994 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,062.00 | 04/21/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | No dispute reported | 06/30/2026 | 1226121460 |
| Recipient | SANOFI US SERVICES INC. | $1,553.35 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123122 |
| Recipient | SANOFI US SERVICES INC. | $395.38 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123125 |
| Recipient | SANOFI US SERVICES INC. | $395.50 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123127 |
| Recipient | SANOFI US SERVICES INC. | $81.75 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123132 |
| Recipient | SANOFI US SERVICES INC. | $79.03 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123136 |
| Recipient | SANOFI US SERVICES INC. | $43.60 | 04/04/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123140 |
| Recipient | SANOFI US SERVICES INC. | $229.71 | 04/03/2025 | Covered Recipient Physician | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226123130 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,100.00 | 03/24/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226121426 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,100.00 | 03/04/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226121445 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/28/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244050838 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $35,030.51 | 02/26/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON | No dispute reported | 06/30/2026 | 1185542860 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $21,000.00 | 02/13/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244050730 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $409.20 | 02/12/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244050836 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,226.71 | 01/30/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192186984 |
| Principal investigator 1 | Amgen Inc. | $26,511.90 | 01/27/2025 | Non-covered Recipient Entity ORSO HEALTH INC | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246646156 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,481.83 | 01/21/2025 | Non-covered Recipient Entity Brian D Modena Orso Health Inc | A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | No dispute reported | 06/30/2026 | 1226121429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,500.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,700.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,800.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,999.00 | 01/16/2025 | Non-covered Recipient Entity ORSO HEALTH INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184147965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.04 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144354 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.04 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144356 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.04 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144358 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.04 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144360 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.41 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144362 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.41 | 01/02/2025 | Non-covered Recipient Entity MODENA ALLERGY AND ASTHMA INC | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144364 |